- Zacks Small Cap Research•9 hours ago
On November 29, 2016 Theralase Technologies (TLT.V) reported third quarter 2016 financial results. Cash used in operating activities was ~$1.3 million for Q3 2016. Net loss for the third quarter was approximately $1.5 million ($0.01/share). The cash balance as of September 30, 2016 was around $800,000. Subsequent to quarter end, on November 10, 2016 the company received net proceeds of ~$4 million from a public offering of 14 million shares. With a cash burn of ~$1-1.5 million/quarter, the company has sufficient capital to carry on its planned operations into the beginning of 2017. The company may need to raise additional capital in 2017 to finance its operations.
- Capital Cube•2 days ago
Categories: Yahoo Finance Get free summary analysis Theralase Technologies, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Theralase Technologies, Inc. – Annidis Corporation, Medx Health Corp., Cynosure, Inc. Class A and CRH Medical Corporation (RHA-CA, MDX-CA, CYNO-US and CRH-CA) that have also reported for this ... Read more (Read more...)
- Accesswire•3 days ago
TORONTO, ON / ACCESSWIRE / November 30, 2016 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization ...
TLT.V : Summary for THERALASE TECHNOLOGIES INC. - Yahoo Finance
Theralase Technologies Inc. (TLT.V)
TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||0.26 - 0.28|
|52 Week Range||0.18 - 0.46|
|PE Ratio (TTM)||-5.89|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|